InMed Pharmaceuticals (INM) Depreciation and Depletion (2019 - 2025)
InMed Pharmaceuticals (INM) posted quarterly Depreciation and Depletion of $12206.0 for Q2 2025, up 124.37% year-over-year from $5440.0 in Q2 2024, and little changed quarter-over-quarter from $12203.0 in Q1 2025.
InMed Pharmaceuticals (INM) Depreciation and Depletion (2019 - 2025) Analysis & Trends
InMed Pharmaceuticals' Depreciation and Depletion history runs 7 years deep, the most recent figure standing at $12206.0 for Q2 2025.
- In Q2 2025, Depreciation and Depletion rose 124.37% year-over-year to $12206.0; the TTM figure through Jun 2025 stood at $50204.0 (up 5.16% YoY), while the FY2025 annual figure was $50204.0, up 5.16% from the prior year.
- Depreciation and Depletion for Q2 2025 stood at $12206.0, roughly flat from $12203.0 in the prior quarter.
- The five-year high for Depreciation and Depletion was $14242.0 in Q4 2023, with the low at $3633.0 in Q1 2021.
- The 5-year median for Depreciation and Depletion is $10586.0 (2023), against an average of $9859.8.
- The sharpest annual moves came in 2021 and 2025: Depreciation and Depletion tumbled 86.48% in 2021, then surged 124.37% in 2025.
- InMed Pharmaceuticals' Depreciation and Depletion stood at $6246.0 in 2021, then advanced by 28.98% to $8056.0 in 2022, then jumped by 76.79% to $14242.0 in 2023, then retreated by 14.27% to $12209.0 in 2024, then dropped by 0.02% to $12206.0 in 2025.
- Business Quant data shows INM's Depreciation and Depletion at $12206.0 in Q2 2025, $12203.0 in Q1 2025, and $12209.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.56 Mn | 1.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 12,206.00 |
| Jun 30, 2025 | 12,206.00 |
| Mar 31, 2025 | 12,203.00 |
| Mar 31, 2025 | 12,203.00 |
| Dec 31, 2024 | 12,209.00 |
| Dec 31, 2024 | 12,209.00 |
| Sep 30, 2024 | 13,586.00 |
| Sep 30, 2024 | 13,586.00 |
| Jun 30, 2024 | 5,440.00 |
| Jun 30, 2024 | 5,440.00 |
| Mar 31, 2024 | 14,220.00 |
| Mar 31, 2024 | 14,220.00 |
| Dec 31, 2023 | 14,242.00 |
| Dec 31, 2023 | 14,242.00 |
| Sep 30, 2023 | 13,839.00 |
| Sep 30, 2023 | 13,839.00 |
| Jun 30, 2023 | 12,916.00 |
| Jun 30, 2023 | 12,916.00 |
| Mar 31, 2023 | 10,586.00 |
| Mar 31, 2023 | 10,586.00 |